[
  {
    "ts": "2026-02-10T00:23:54+00:00",
    "headline": "Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio",
    "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...",
    "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "67b2f8ee-e066-32bb-a421-7d4a55fb3212",
      "content": {
        "id": "67b2f8ee-e066-32bb-a421-7d4a55fb3212",
        "contentType": "STORY",
        "title": "Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...",
        "pubDate": "2026-02-10T00:23:54Z",
        "displayTime": "2026-02-10T00:23:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-uses-glp-1-002354758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T09:10:00+00:00",
    "headline": "Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?",
    "summary": "The stock has climbed in the triple digits over the past three years.",
    "url": "https://www.fool.com/investing/2026/02/10/could-eli-lilly-turn-todays-glp1-obesity-boom-into/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "65cdd472-6bbe-3900-ba83-d77d0c3c534a",
      "content": {
        "id": "65cdd472-6bbe-3900-ba83-d77d0c3c534a",
        "contentType": "STORY",
        "title": "Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?",
        "description": "",
        "summary": "The stock has climbed in the triple digits over the past three years.",
        "pubDate": "2026-02-10T09:10:00Z",
        "displayTime": "2026-02-10T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3575ec1d5e649814f22b2c433c57d1da",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "An investor smiles while looking at something on a phone.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iIZVKjYYT59JuL3mi9iIrQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/3575ec1d5e649814f22b2c433c57d1da.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/O2.JzyyIdj5T4__W1T8oMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3575ec1d5e649814f22b2c433c57d1da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/10/could-eli-lilly-turn-todays-glp1-obesity-boom-into/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/could-eli-lilly-turn-todays-091000394.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T05:01:00+00:00",
    "headline": "Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs",
    "summary": "Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.",
    "url": "https://www.thedailyupside.com/industries/healthcare/novo-nordisk-launches-suit-to-knock-out-hims-hers-weight-loss-knockoffs/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "389b6907-4e58-3613-a557-2518d1652653",
      "content": {
        "id": "389b6907-4e58-3613-a557-2518d1652653",
        "contentType": "STORY",
        "title": "Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs",
        "description": "",
        "summary": "Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.",
        "pubDate": "2026-02-10T05:01:00Z",
        "displayTime": "2026-02-10T05:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/cc9fcb1ff5ae299bf83351d83efba856",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of Novo Nordisk CEO Mike Doustdar.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H6m4g3K9D__F0B_UM7qnbw--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/cc9fcb1ff5ae299bf83351d83efba856.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Oi09qg9f1oDO_3C0sotpQQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/cc9fcb1ff5ae299bf83351d83efba856.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/novo-nordisk-launches-suit-to-knock-out-hims-hers-weight-loss-knockoffs/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-launches-suit-knock-050100057.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "KR"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T14:35:00+00:00",
    "headline": "Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.",
    "summary": "Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?",
    "url": "https://www.fool.com/investing/2026/02/10/eli-lilly-is-partnering-with-gene-editing-start-up/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7b8152d5-3599-3fb9-ac4a-992668716cf4",
      "content": {
        "id": "7b8152d5-3599-3fb9-ac4a-992668716cf4",
        "contentType": "STORY",
        "title": "Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.",
        "description": "",
        "summary": "Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?",
        "pubDate": "2026-02-10T14:35:00Z",
        "displayTime": "2026-02-10T14:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/51e174e39ebb12921e94819c96cc931e",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "A person using an injection pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BJSPhZ0KEwr.zucNuPUtBw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/51e174e39ebb12921e94819c96cc931e.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nbma.1IT0jIgKwinqodXGg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/51e174e39ebb12921e94819c96cc931e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/10/eli-lilly-is-partnering-with-gene-editing-start-up/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-partnering-gene-editing-143500070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]